Homozygosity of germ line JAK2 46/1 haplotype contributes to phenotype and outcome diversity in polycythemia vera

Blood Neoplasia · Published 2026-06-05 · DOI 10.1016/j.bneo.2026.100256

Free full text

Authors (17)

Paola Guglielmelli, Chiara Maccari, Manjola Balliu, Giuseppe G. Loscocco, Naseema Gangat, Valentina Boldrini, Giulio Capecchi, Leonardo Signori, Alessio Enderti, Giada Rotunno, Chiara Paoli, Sofia Danesi, Cecilia Matteoli, Francesco Mannelli, Tiziano Barbui, Ayalew Tefferi, Alessandro Maria Vannucchi

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Guglielmelli, P., Maccari, C., Balliu, M., et al. (2026). Homozygosity of germ line JAK2 46/1 haplotype contributes to phenotype and outcome diversity in polycythemia vera. Blood Neoplasia. https://doi.org/10.1016/j.bneo.2026.100256

Related articles

• Somatic UBA1 mutations in pediatric MDS/AML: first cases suggest distinct pathogenesis from adult VEXAS syndrome · Blood Neoplasia · 2026 · Same journal
• Clinical features and outcomes of MPN with concurrent MPL and JAK2/CALR Mutations · Blood Neoplasia · 2026 · Same journal
• Timing of response in patients with relapsed/refractory FLT3mut+ acute myeloid leukemia treated with gilteritinib · Blood Neoplasia · 2026 · Same journal
• Ixazomib with chemotherapy for childhood relapsed acute lymphoblastic leukemia: a TACL consortium report · Blood Neoplasia · 2026 · Same journal
• CD8+CD38+ T cells identify functional high-risk multiple myeloma after autologous transplant: BMT CTN 0702 correlates · Blood Neoplasia · 2026 · Same journal
• Abnormal serum immunofixation patterns are common after BCMA CAR-T in multiple myeloma and are preceded by immune events · Blood Neoplasia · 2026 · Same journal
• Real-world outcomes of patients with multiple myeloma who reach third-line therapy: a Canadian report · Blood Neoplasia · 2026 · Same journal
• Deletion 11q, monosomy 13, and deletion 13q in noncomplex karyotype acute myeloid leukemia · Blood Neoplasia · 2026 · Same journal
• Myeloid cell–mediated killing of B-ALL by CD38 and CD20 IgA antibody variants is enhanced by CD47/SIRPα interference · Blood Neoplasia · 2026 · Same journal
• Favezelimab plus pembrolizumab for anti–PD-1–refractory classic Hodgkin lymphoma: an open-label phase 1/2 study · Blood Neoplasia · 2026 · Same journal